The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 08, 2016
Filed:
Feb. 10, 2014
Applicant:
Paratek Pharmaceuticals, Inc., Boston, MA (US);
Inventors:
Mark L. Nelson, Norfolk, MA (US);
Kwasi Ohemeng, West Haven, CT (US);
Assignee:
Paratek Pharmaceuticals, Inc., Boston, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/65 (2006.01); C07C 237/26 (2006.01); C07C 235/70 (2006.01); C07C 251/48 (2006.01); C07C 255/41 (2006.01); C07C 271/22 (2006.01); C07C 271/54 (2006.01); C07C 271/58 (2006.01); C07C 275/42 (2006.01); C07C 275/54 (2006.01); C07C 279/18 (2006.01); C07C 311/06 (2006.01); C07C 311/08 (2006.01); C07C 333/08 (2006.01); C07C 335/22 (2006.01); C07C 381/10 (2006.01); C07D 295/155 (2006.01); C07D 295/185 (2006.01); C07D 317/60 (2006.01); C07F 9/24 (2006.01); C07F 9/40 (2006.01);
U.S. Cl.
CPC ...
C07C 237/26 (2013.01); C07C 235/70 (2013.01); C07C 251/48 (2013.01); C07C 255/41 (2013.01); C07C 271/22 (2013.01); C07C 271/54 (2013.01); C07C 271/58 (2013.01); C07C 275/42 (2013.01); C07C 275/54 (2013.01); C07C 279/18 (2013.01); C07C 311/06 (2013.01); C07C 311/08 (2013.01); C07C 333/08 (2013.01); C07C 335/22 (2013.01); C07C 381/10 (2013.01); C07D 295/155 (2013.01); C07D 295/185 (2013.01); C07D 317/60 (2013.01); C07F 9/2475 (2013.01); C07F 9/4006 (2013.01); C07C 2101/08 (2013.01); C07C 2101/10 (2013.01); C07C 2101/16 (2013.01); C07C 2103/46 (2013.01);
Abstract
The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.